Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Autor: Emmanuel Langlois, Vincent Germain, Thierry Schaeverbeke, Marc Scherlinger
Přispěvatelé: Centre Émile Durkheim (CED), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)-Sciences Po Bordeaux - Institut d'études politiques de Bordeaux (IEP Bordeaux), Ecole Supérieure d'Informatique Electronique Automatique [Paris] (ESIEA), Service de rhumatologie, CHU Bordeaux [Bordeaux], Sciences Po Bordeaux - Institut d'études politiques de Bordeaux (IEP Bordeaux)-Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
Health Knowledge
Attitudes
Practice
Acceptance rate
Pharmacist
DMARDs (biologic)
Etanercept
Medication Adherence
Arthritis
Rheumatoid
Patient perspective
Anti-TNF
03 medical and health sciences
0302 clinical medicine
Rheumatology
Spondylarthritis
Spondyloarthritis
medicine
Humans
In patient
030212 general & internal medicine
Prospective Studies
Rheumatoid arthritis
Biosimilar Pharmaceuticals
030203 arthritis & rheumatology
[SHS.SOCIO]Humanities and Social Sciences/Sociology
business.industry
Age Factors
Biosimilar
Patient Preference
Middle Aged
medicine.disease
3. Good health
Anesthesiology and Pain Medicine
Sociological Factor
Family medicine
Antirheumatic Agents
Female
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Rheumatology department
business
medicine.drug
Zdroj: Seminars in Arthritis and Rheumatism
Seminars in Arthritis and Rheumatism, WB Saunders, 2019, 48 (5), pp.927-932. ⟨10.1016/j.semarthrit.2018.07.005⟩
ISSN: 0049-0172
DOI: 10.1016/j.semarthrit.2018.07.005⟩
Popis: International audience; Objective : To study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with rheumatic disease.Methods : Patients with a well-controlled rheumatic disease consulting in our rheumatology department were offered the switch for SB4. After oral and written information concerning biosimilar, free choice to accept the switch was left to the patients. The main outcome was primary switch acceptance rate defined by switch acceptance during the initial consult. Real switch adherence, socio-cultural factors and beliefs influencing switch acceptance rate were retrieved during a telephonic interview at distance from the consultation.Results : Fifty-two patients were eligible for the switch: 32 (62%) with spondyloarthritis and 20 (38%) with rheumatoid arthritis. The primary acceptance rate was 92% (48/52). Patients refusing the switch were more likely to report a bad opinion on generic drugs (100% vs 11%, p
Databáze: OpenAIRE
Externí odkaz: